{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:24:59Z","timestamp":1766269499663,"version":"build-2065373602"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This report presents the case of a 70-year-old female patient with hepatocellular carcinoma (HCC) who was hospitalized for fever of unknown origin. We confirmed the diagnosis of HCC with lymphadenopathy through needle biopsy. The patient experienced hypertension and malaise after therapy with tislelizumab plus lenvatinib. Additionally, there was a persistent decrease in T3 and T4 levels accompanied by elevated TSH levels. During treatment, tumor regression and notable shrinkage of enlarged lymph nodes met the criteria for surgical intervention. However, since the patient\u2019s family declined surgery, the tumor subsequently progressed, resulting in clinical deterioration. This case highlights the uncommon occurrence of hypothyroidism after targeted immunotherapy in HCC patients and emphasizes the critical role of monitoring thyroid function in prognosis assessment. Conclusion: Hypothyroidism following combination therapy with tislelizumab and lenvatinib in HCC may indicate a favorable therapeutic response. Early surgical intervention is recommended once tumor shrinkage and symptom improvement occur.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1630058","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:24:17Z","timestamp":1761891857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tislelizumab plus lenvatinib for hepatocellular carcinoma with hypothyroidism. A case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Biaobiao","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renya","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatictreatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"14","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"B4","article-title":"Clinical efficacy of tislelizumab combined with lenvatinib in the treatment of advanced hepatocellular carcinoma","author":"Wu","year":"2025","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0140","article-title":"Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma","volume":"66","author":"Koizumi","year":"2019","journal-title":"Endocr J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"Galle","year":"2021","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn","article-title":"Efficacy analysis of tislelizumab injection combined with anlotinib as first-line treatment for advanced lung squamous cell carcinoma","volume":"52","author":"Xie","year":"2024","journal-title":"Chin J Clinician"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.20.02291","article-title":"Clinical cancer advances 2020: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"38","author":"Markham","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3RI has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12916-024-03356-5","article-title":"Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial","volume":"22","author":"Xu","year":"2024","journal-title":"BMC Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10480-y","article-title":"Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958869","article-title":"PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10198-3","article-title":"Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study","volume":"15","author":"Cao","year":"2021","journal-title":"Hepatol Int"},{"key":"B15","article-title":"Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors combined with immune checkpoint inhibitors in the treatment of sarcoma","volume":"12","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01249-7","article-title":"Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma","volume":"14","author":"Miyajima","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.12173\/j.issn.1005-0698.202305080","article-title":"Rapid progression of colitis caused by lenvatinib combined with tislelizumab in treatment of hepatocellular carcinoma: a case report","volume":"33","author":"Ma","year":"2021","journal-title":"J Pharmacoepidemiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113078","article-title":"Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy","volume":"12","author":"Shomura","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.11952\/j.issn.1007-1954.2025.03.001","article-title":"Interpretation of the key points of the guidelines for the diagnosis and treatment of primary liver cancer (2024 edition)","volume":"37","author":"Caifeng","year":"2020","journal-title":"J Hepatobiliary Pancreatic Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-8157","article-title":"Analysis of 61 cases of adverse reactions caused by lenvatinib","volume":"20","author":"Yang","year":"2023","journal-title":"Chin J Drug Appl Monitoring"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.11768\/nkjwzzzz20240304","article-title":"Immune-related thyroid dysfunction is associated with improved prognosis in patients with unresectable\/advanced hepatocellular carcinoma","volume":"30","author":"Zhang","year":"2024","journal-title":"J Emergency Crit Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000531182","article-title":"Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma","volume":"13","author":"Song","year":"2023","journal-title":"Liver Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33813","article-title":"Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma","volume":"150","author":"Xu","year":"2022","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12032-024-02309-5","article-title":"The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma","volume":"41","author":"Liu","year":"2024","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.987401","article-title":"Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study","volume":"13","author":"Lu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13755","article-title":"An underdiagnosed hypothyroidism and its clinical significance in patients with advanced hepatocellular carcinoma","volume":"26","author":"Shao","year":"2021","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad277","article-title":"Prognoses of patients treated with surgical therapy versus continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma: a multicenter real-world study","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.11952\/j.issn.1007-1954.2024.05.007","article-title":"Kaixintilizumab, lenvatinib combined with TACE successfully transformed huge hepatocellular carcinoma: a case report","volume":"36","author":"Li","year":"2024","journal-title":"J Hepatobiliary Pancreatic Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01909-4","article-title":"A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report","volume":"17","author":"Gyoda","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3760\/cma.j.cn115610-20240228-00135","article-title":"Chinese expert consensus on transformation and perioperative treatment of primary liver cancer (2024 edition)","volume":"23","year":"2024","journal-title":"Chin J Digestive Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3760\/cma.J.c.n113884-20240123-00028","article-title":"Unresectable hepatocellular carcinoma (HCC) conversion therapy","volume":"30","author":"Tan","year":"2024","journal-title":"Res Prog liver gallbladder Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030720","article-title":"Liver transplantation for pediatric liver cancer","volume":"12","author":"Sindhi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.16440\/J.CNKI.1674-8166.2025.04.08","article-title":"Research on the mechanism of immune surveillance deficiency in autoimmune hyperthyroidism based on genotype waterfall mechanism","volume":"26","author":"Li","year":"2020","journal-title":"J Chronic Diseases"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:24:26Z","timestamp":1761891866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1630058"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1630058","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1630058"}}